RIP1-HAT1-SirT complex identification and targeting in treatment and prevention of cancer by Carafa, Vincenzo et al.
Translational Cancer Mechanisms and Therapy
RIP1–HAT1–SIRT Complex Identification and
Targeting in Treatment and Prevention
of Cancer
Vincenzo Carafa1, Angela Nebbioso1, Francesca Cuomo1, Dante Rotili2,
Gilda Cobellis1, Paola Bontempo1, Alfonso Baldi3, Enrico P. Spugnini4,
Gennaro Citro5, Angela Chambery3, Rosita Russo3, Menotti Ruvo6, Paolo Ciana7,
Luca Maravigna7, Jani Shaik8, Enrico Radaelli9,10, Pasquale De Antonellis11,
Domenico Tarantino2, Adele Pirolli2, Rino Ragno2, Massimo Zollo11,12,
Hendrik G. Stunnenberg8, Antonello Mai2,13, and Lucia Altucci1
Abstract
Purpose: Alteration in cell death is a hallmark of cancer. A
functional role regulating survival, apoptosis, and necroptosis has
been attributed to RIP1/3 complexes.
Experimental Design: We have investigated the role of RIP1
and the effects of MC2494 in cell death induction, using different
methods as flow cytometry, transcriptome analysis, immunopre-
cipitation, enzymatic assays, transfections, mutagenesis, and
in vivo studies with different mice models.
Results:Here, we show that RIP1 is highly expressed in cancer,
and we define a novel RIP1/3–SIRT1/2–HAT1/4 complex. Mass
spectrometry identified five acetylations in the kinase and death
domain of RIP1. The novel characterized pan-SIRT inhibitor,
MC2494, increases RIP1 acetylation at two additional sites in the
death domain. Mutagenesis of the acetylated lysine decreases
RIP1-dependent cell death, suggesting a role for acetylation of
theRIP1 complex in cell deathmodulation. Accordingly,MC2494
displays tumor-selective potential in vitro, in leukemic blasts
ex vivo, and in vivo in both xenograft and allograft cancer models.
Mechanistically, MC2494 induces bona fide tumor-restricted
acetylated RIP1/caspase-8–mediated apoptosis. Excitingly,
MC2494 displays tumor-preventive activity by blocking 7,12-
dimethylbenz(a)anthracene–induced mammary gland hyper-
proliferation in vivo.
Conclusions: These preventive features might prove useful in
patients who may benefit from a recurrence-preventive
approach with low toxicity during follow-up phases and in
cases of established cancer predisposition. Thus, targeting the
newly identified RIP1 complex may represent an attractive
novel paradigm in cancer treatment and prevention. Clin Cancer
Res; 24(12); 2886–900. 2018 AACR.
Introduction
Cell death is a normal process responsible of tissue homeo-
stasis. Different pathways of cell death have been described (1)
and recently classified (2, 3). Both the classical apoptosis, autop-
hagy, and necroptosis [a new form of programmed cell death
(PCD); ref. 4] have been causally connected to cancer. The RIP1
kinase has been reported displaying a functional role in either
regulation of survival or apoptosis andnecroptosis (5) and is a key
regulator of many signaling pathways such as inflammation (6),
oxidative stress, plasma membrane permeabilization, and cyto-
solic ATP reduction (7). RIP1, initially identified as a Fas-inter-
acting protein (8, 9), is also named "a death domain kinase",
having a 112-amino acid death domain (DD) at its C-terminus.
RIP1 is the founding member of the RIP family (10). RIP1 kinase
activity is responsible for RIP3 phosphorylation (11), and sub-
sequently, for MLKL phosphorylation and trimerization, which is
necessary to activate the necroptotic death pathway (12, 13). The
fact that other RIP family members do not compensate for RIP1
deficiency suggests a unique role for RIP1 (10, 14). The central
deregulation of cell death in tumorigenesis has become clear, yet,
very little is known of RIP1 and cancer. RIP1 and RIP3, as well as
necroptosis, are deregulated in many types of cancers, thus
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presenting a potential therapeutic targets in treatment of
cancers resistant to chemotherapeutic agents or to apoptosis
inducers (15, 16). Here, we show that RIP1 is highly expressed
in cancer, and we define a novel RIP1/3–SIRT1/2–HAT1/4 com-
plex in which RIP1 is subject to regulation by acetylation. Excit-
ingly, mutation of the acetylated lysine decreases RIP1-dependent
cell death, suggesting a role for acetylation of the RIP1 complex in
cell death deregulation and function. Increasing RIP1 acetylation
with anovelmultiacting SIRT inhibitor,MC2494, displays tumor-
selective therapeutic potential in vitro, ex vivo, and in vivo inducing
tumor-restricted apoptosis. Extraordinarily, MC2494 shows
tumor-preventive activity in vivo. Thus, targeting the newly iden-
tified RIP1 complex and its acetylation may represent a feasible
and attractive novel paradigm for therapeutic purposes in cancer
treatment and prevention.
Materials and Methods
Cell lines, primary cells, and ligands
U937, NB4, HL-60, K562, U266, JURKAT, MCF7, MDA-
MB231, LnCap, NIH3T3, and HCT116 cells were purchased from
DSMZ. MCF10A was purchased from the ATCC. HEK293FT and
HACAT cells were ordered from Thermo Fisher Scientific. EPN,
hMSC, and primary normal amniocytes cells were obtained from
University of Campania Luigi Vanvitelli, Italy. All cell lines and
primary cells were grown following standard protocols. A more
detailed description is reported in Supplementary Material and
Methods. Mycoplasma contamination was regularly examined
using a EZ-PCR Mycoplasma kit (Biological Industries), prior to
freezing working stabs. All cell lines were tested and authenticat-
ed. Cells were used for experiments within 10 to 20 passages and
then discarded. AGK2 (Sigma) and MC2494 (and derivatives)
were dissolved in DMSO and used at 5  105 mol/L. MC2494
was synthetized byUniversity Sapienza, Rome, Italy. ForMC2494
synthesis details, see Supplementary Notes. EX527 (Alexis) was
dissolved in DMSO (Sigma) and used at 5  106 mol/L, unless
otherwise specified. Staurosporine (Alexis) was dissolved in
DMSO and used at 2  106 mol/L. Suramin (Bio Mol) was
used at 5  105 mol/L.
Antibodies
H3K9-14ac, H3K9ac, H3K56ac, and RIP1 were from Diag-
enode and BD. H4ac and p53ac were from Upstate. H3, Acetyl-
lysine, H4 H2A.X (phS139), CPS1, MLYCD, SIRT1, SIRT2,
PCAF, and KAT1/HAT1 were from Abcam. ATM (phS1981)
and ATR were from R&D. Acetyl-tubulin was from Sigma.
ERK1/2, IAP, FLIP-L, PARP, and RIP3 were from Santa Cruz
Biotechnology. Bax, t-Bid, caspase-3, caspase-8, CYLD, IKKg ,
FADD, FAS, and BCL2 were from Cell Signaling Technology.
HAT4 was from myBiosurce.
Morphologic analysis
For U937, MCF7, andMDA-MB-231 cancer cell lines, morpho-
logic analysis was performed, using bright field light microscopy
(20X).
Reagents
Z-VAD, Z-IETD, and Z-LEHD (R&D) were used at 50 mmol/L.
N-acetyl-cysteine (NAC) and Nec-1 (Sigma) were used at 50
and 100 mmol/L, respectively. Note that 1 mg of RIP1 and
RIP(K596/599R) were transfected. H2O2 and PIETC (Sigma) were
used at 1 mmol/L and 10 mmol/L, respectively. C646 (Sigma)
was used at 50 mmol/L.
Cell vitality, cell cycle, differentiation, death, and apoptosis
To study cell vitality, experiments were performed in triplicate.
Cells were diluted 1:1 in Trypan blue (Sigma) and counted. Cell
cycle and differentiation analysis was performed in triplicate as
reported previously (17). Apoptosis was measured by caspase-3–
7, 8, and 9 (R&D) and quantified by FACS (BD). Apoptosis was
measured as pre-G1 DNA fragmentation or by Annexin V detec-
tion as in ref. (17). Apoptosis versus necrosis was measured using
an apoptosis/necrosis kit as suggested by the supplier (Enzo life
sciences).
SIRTs, HDACs, and PCAF assays
SIRT1, 2, and 3 assay experiments were performed as sug-
gested by the supplier (BioMol). Moreover, for SIRT1, addi-
tional assays were performed: (i) HRTF assay; (ii) BioMol assay
with a different excitation/emission range; (iii) SIRTainty assay
(Millipore). SIRT3 and 6 assays were performed in vitro follow-
ing the supplier's instructions (ENZO life and Cayman, respec-
tively). To evaluate the action of MC2494 on SIRT4 and 5, we
IPed CPS1 and MLYCD (reported as substrates for SIRT4 and
SIRT5, respectively), and they used in a radiolabelling assay.
Finally, both histone deacetylase (HDAC) and PCAF radioac-
tive assays were performed according to supplier's instructions
(Upstate). A detailed description of in vitro assays is reported in
Supplementary Material and Methods.
Proliferation and migration analysis in real time
Proliferation and migration analyses were evaluated in
MDA-MB231 cells and performed according to the supplier
instruction (xCELLigence; Roche). A detailed description is in
Supplementary Material and Methods.
RNA, RT-PCR, and chromatin immunoprecipitation
Total RNAwas extractedwith Trizol (Invitrogen) and converted
into cDNA using VILO (Invitrogen). RNA extraction and RT-PCR
are detailed in the Supplementary Methods. Chromatin
Translational Relevance
It is becoming increasingly clear that cancer is not only a
genetic but also an epigenetic disease. Here, we identified a
novel RIP1–SIRT/HAT1 complex controlling survival and
death via regulation of RIP1 acetylation. Notwithstanding the
increasing interest for sirtuins modulation in tumorigenesis,
very little known is on their involvement in programmed cell
death programs. A major goal of epi-drug development is to
increase the therapeutic index and limit development of
resistance. One attractive option is to combine anticancer
effects with drugs able to prevent neoplasia. Here, we have
developed and report on a novel pan-SIRT inhibitor that alters
HAT1/SIRT equilibrium in the RIP1 complex, showing bona
fide anticancer-selective and cancer-preventive activities
in vitro, ex vivo, and in vivo. Our work expands the current
views in the drug discovery andmight prove useful in patients
who may benefit from a recurrence-preventive approach with
low toxicity during follow-up phases and in cases of estab-
lished cancer predisposition.
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immunoprecipitation (ChIP) was carried out as previously
reported (18) using H3K9-14ac. More details are in Supplemen-
tary Material and Methods.
Protein extraction
After PBS wash, cell pellets were suspended in lysis buffer
(50 mmol/L Tris-HCl, pH 7.4, 150 mmol/L NaCl, 1% NP40,
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Figure 1.
RIP1 expression, interactome,
acetylation, and location. A, RIP1
protein expression in different
cancer cell lines. B, Mass
spectroscopy analysis of
RIP1 interactome performed in
HEK293FT RIP1-GFP cells.
C,Western blot analysis of RIP1-GFP
immunoprecipitated in HEK293FT
cells shows the presence of RIP1,
SIRT1, KAT1/HAT1, SIRT2, HAT4, and
RIP3 proteins. D, Western
blot analysis of RIP1-GFP
immunoprecipitated with GFP
Trap_A beads in HEK293FT cells.
Top: WB with ac-lysines antibody
reveals RIP1 acetylation levels;
bottom: WB for RIP1 and KAT1/HAT1.
E, Schematic representation of
acetylated lysines and their
localization within the RIP1
subdomains. F, Nucleo/Cytosol
localization of RIP1, SIRT1,and HAT1
performed in HEK293FT cells.
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Figure 2.
The novel pan-SIRT inhibitor MC2494
affects RIP1 acetylation. A, Structure
of MC2494. B, In vitro inhibition of
SIRT1/2/3/4/5/6 by MC2494.
Enzymatic assays carried out with
MC2494 (50 mmol/L), Suramin (100
mmol/L), EX527 (5 mmol/L), and AGK2
(50 mmol/L) were used as controls.
C, mRNA evaluation of SIRT1, SIRT2,
and SIRT3 in HEK293FT, MDA-MB231,
and U937 cancer cells. D, mRNA
evaluation of SIRT1, SIRT2, and SIRT3
in HACAT "normal" cells. E, Western
blot analysis of RIP1-GFP
immunoprecipitated in HEK293FT.
Top: WB with ac-lysines antibody
reveals a strong increase of RIP1
acetylation levels after MC2494
treatment; Lower: WB for RIP1.
F, Schematic representation of the
acetylated lysines upon MC2494 and
their localization within the RIP1
subdomains. Extracted ion
chromatogram corresponding to the
monoacetylated RIP1 peptides.
G, Molecular complex analysis
after MC2494 treatment. Western
blot analysis of RIP1-GFP
immunoprecipitates in HEK293FT cells
confirms the presence of SIRT1, HAT1,
RIP1, HAT4, and RIP3 proteins. After
MC2494 treatment, a reduction of SIRT1
and a slight increase of HAT1 are
observed.H, Evaluation of acetyl RIP1 in
SIRT1 loss-of-function condition.
Graph showed the mean of three
independent experiments with error
bars indicating SD.
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10 mmol/L NaF, 1 mmol/L PMSF, and protease inhibitor cock-
tail). The lysis reaction was carried out for 15 minutes at 4C.
Finally, the samples were centrifuged at 13,000 rpm for 30
minutes at 4C and protein concentration quantified by Bradford
assay (Bio-Rad).
Histone extraction
After stimulation with the indicated compounds, cells were
collected and washed 2 times with PBS. Pellets were resus-
pended in triton extraction buffer [TEB; PBS containing 0.5%
Triton X 100 (v/v), 2 mmol/L PMSF, 0.02% (w/v) NaN3], and
the lysis procedure was performed for 10 minutes at 4C. The
samples were centrifuged at 2,000 rpm for 10 minutes at 4C
and pellets washed in TEB (half volume). Samples were then
resuspended in 0.2 N HCl, and acid histone extraction was
carried out overnight at 4C. The next day the supernatant was
recovered and protein concentration quantified by Bradford
assay (Bio-Rad).
Nucleus/cytosol extraction
Pellets were resuspended in 2 to 2.5 volumes of NP-40 Buffer
(10 mmol/L Tris-HCl, pH 7.0, 10 mmol/L NaCl, 3 mmol/L
MgCl2, 30 mmol/L Sucrose, 0.5 % NP-40) and incubated for
10' on a rotating platform at 4C. After centrifugation at 1,000
rpm for 10 minutes at 4C, the supernatants were transfer in a
new tube (cytosolic fraction). Pellets (nuclei) were suspended
in 2 mL of NP-40 buffer and centrifuged at 3,000 rpm for 10
minutes. The supernatants were removed, and the pellet of
nuclei was washed in Lysis Buffer (20 mmol/L Tris-HCl, pH 8,
137 mmol/L NaCl, 10% glycerol, 1% NP-40, 2 mmol/L EDTA)
for 10 minutes in ice. The suspension was sonicated (4  30
"on/30" off high power) and centrifugated. The surnatant
(nuclear proteins) was transferred in a new tube and stored at
20C.
Western blot
Note that 50 mg of proteins were loaded on 10% to 15%
polyacrylamide gels. Histone extract (5–10 mg) was loaded on
15% polyacrylamide gel. The nitrocellulose filters were stained
with Ponceau red (Sigma) as additional control for equal loading.
The antibodies used are listed in Supplementary Material and
Methods.
Immunoprecipitation assay
MDA-MB-231 and HEK293FT cells were lysed in NP-40
(0.5%), Tris-HCl pH 8.0 (20 mmol/L), NaCl (150 mmol/L),
PMSF (1 mmol/L), 10% glycerol, EDTA (1 mmol/L), and 1X
protease inhibitor mix (Sigma) for 20' on ice. Cell debris was
removed, and the protein-soluble fraction was incubated with
antibody overnight at 4C. The immune complexes were immu-
noprecipitated with Sepharose-protein A/G Plus (Santa Cruz
Biotechnology) or with GFP-TRAP_A beads (Cromotech) for 2
hours at 4C. Proteins were then eluted, resuspended, and ana-
lyzed by Western blot.
CETSA assay
HEK293FT cells were harvested and washed with PBS after
treatment with MC2494 (50 mmol/L) and an equal amount of
DMSO, as control, for 1 hour. The respective samples were
suspended in PBS (1.5 mL), divided into aliquots (100 mL), and
heated at different temperatures (25C–37C–44C–53C–57C)
for 3 minutes by Thermo Mixer (Eppendorf), followed by
cooling for 3 minutes at 4C. After incubation, lysis buffer
(100 mL) was added to the samples and incubated for 15minutes.
The samples were then centrifuged at 13,000 rpm for 30 minutes
at 4C, the supernatant was removed, and protein concentration
was determined using a Bradford assay (Bio-Rad). Of the total
protein extract, 20mgwas loadedon10%SDS-PAGE, andWestern
blot analysis was performed. The antibodies used were SIRT1,
SIRT2, and SIRT3 (Abcam).
Transfections
RIP1-GFP and RIP-GFP(K596/599R) were transfected in
HEK293FT cells with Lipofectamine 2000 (Invitrogen). TRAIL
promoter mutants were used as previously described (17).
RNA interference
To silence RIP1 and caspase-8 were used specific predesigned
siRNA for RIP1 (SI00288092) and CASP8 (SI02661946) pur-
chased from Qiagen. U937 cells were transfected with Nucleo-
fector Technology, and siRNA was used at 1 mmol/L. To silence
SIRT1 gene expression, HEK293 cells were transfected with a
specific SIRT1 siRNA directed against human SIRT1 (On-Target
plus SMART pool), which was purchased from Dharmacon, and
with a specific predesigned siRNA for SIRT1 purchased from
Ambion. A scrambled siRNA was used as a control. Cells were
transfected with the indicated siRNAs at 50 nmol/L of concen-
tration, using DharmaFECT1 Transfection reagent (Dharmacon).
Allograft experiments
All animal procedures were conducted according to national
and international guidelines. The breast cancer 4T1–Luc model
was a gift from Dr. P. Steeg (NIH, Bethesda). Approval was
obtained from the Institutional Animal Care and Ethical Com-
mittee at CEINGE and "Federico II" University of Naples (Proto-
col #29, 01/09/2009), and the Italian Ministry of Health, Dipar-
timento Sanita Pubblica Veterinaria D.L. 116/92, confirming that
all of the experiments conform to the relevant regulatory stan-
dards. A detailed description of procedures is in Supplementary
Material and Methods.
Figure 3.
MC2494 affects proliferation and induces caspase-8–dependent apoptosis. A, Proliferation curve in U937 cells in the presence of the indicated compounds
and analysis of cell death as evaluation of pre-G1 phase.MC2494 andAGK2were used at 50mmol/L, and EX527 at 5mmol/L.B, Left: MDA-MB231 cell growth following
MC2494, monitored in real time. Right: Migration rate measure as slope (1/h) monitored within the 24 hours from the indicated treatments. MC2494 was
used at 50 mmol/L. C, Induction of pre-G1 phase upon MC2494 treatment in cancer and normal cell lines.D and E, FACS analysis of caspase-8, -9, and -3/7 activation
and MMD. The experiments were carried out in U937 cells upon treatment with MC2494 (50 mmol/L). F, Western blot analysis of DNA damage evaluation
performed in U937 cells upon treatmentwithMC2494 (50 mmol/L).G,Apoptosis induced byMC2494 (50mmol/L and 24 hours) in U937 cells is selectively blocked by
pan- and caspase-8 inhibitors (Z-VAD and IETD), but not by caspase-9 (LEHD). H, ROS production following MC2494 (50 mmol/L), PIETC (10 mmol/L), and H2O2
(1 mmol/L) for 24 hours, and MC2494-mediated apoptosis was blocked by NAC (50 mmol/L). Curves and graph presented showed the mean of at least three
different experiments with error bars indicating standard deviation.
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Cancer prevention and mito-mice
MC2494 was dissolved in DMSO and diluted 1:5 in vehicle
(corn oil). 7,12-dimethylbenz(a)anthracene (DMBA; Sigma)was
dissolved in acetone (8 mmol/L). Eight female MITO-Luc mice
(repTOPmitoIRE; Italy; ref. 19) of 2months of agewere housed in
plastic cages and fed ad libitum with a standard diet (4RF21
standard diet; Mucedola). Room temperature was within 22 to
25Candhumidity of 50%10%.Animalsweredivided into two
groups and s.c. treated with 50 mg/kg MC2494 or placebo (corn
oil) every day at 02.00PM for 9days. At day 6,micewere subjected
to a single s.c. intraglandular injection of DMBA (left) or vehicle
(right gland); at day 9, after the last in vivo imaging acquisition,
mice were sacrificed, mammary glands explanted for ex vivo
imaging and fixed for analysis. A detailed description is in Sup-
plementary Material andMethods. Imaging in vivo procedure was
as in refs. (20, 21) and is detailed in Supplementary Material and
Methods.
Xenograft experiments and pulse generator in vivo
All procedures involving animals and their carewere conducted
in conformity with institutional guidelines, which are in compli-
ance with national (D.L. No. 116, G.U., Suppl. 40, Feb. 18, 1992;
Circolare No. 8, G.U., July 1994) and international (EEC Council
Directive 86/609, O.J. L 358. 1, December 12, 1987; Guide for the
Care and Use of Laboratory Animals, United States National
Research Council, 1996) laws. A detailed description of proce-
dures and histology, immunohistochemistry, and TUNEL assay
in vivo is given in Supplementary Material and Methods.
High-resolution nanoLCtandem mass spectrometry mass
spectrometry analysis was performed on a Q Exactive Orbitrap
mass spectrometer equipped with an EASY-Spray nano-electro-
spray ion source (Thermo Fisher Scientific) and coupled to a
Thermo Scientific Dionex UltiMate 3000RSLC nano system
(Thermo Fisher Scientific). A detailed description and data pro-
cessing are in Supplementary Material and Methods.
IP-Mass spectrometry
Formass spectrometry analysis, RIP1was overexpressed using a
GFP-tagged vector and immunoprecipitated with GFP-trap_A
beads. The data-dependent mass spectra were acquired with the
LTQ-Orbitrap mass spectrometer (Thermo Scientific). A detail
description of these procedures is in Supplementary Material and
Methods.
Results
RIP1 is highly expressed in cancer cells and interacts withHAT1
and SIRT1/2
Programmed necrosis or necroptosis is an alternative form of
PCD in which the RIP1–RIP3 complex displays a functional role.
To explore RIP1 function in cancer, RIP1 protein levels were
evaluated in different cancer cells (Fig. 1A), showing a generally
high expression of RIP1. Mass spectrometry analysis performed
after RIP1 immunoprecipitation (ProteomeXchange, PRIDE
database, dataset identifier PXD007198) identified a new
RIP1–HAT1–SIRT1 complex (Fig. 1B). The RIP1–HAT1–SIRT1
complex was validated by Western blot. Both RIP3 (with a weak
signal) and HAT4, known interactors of RIP1 and HAT1,
respectively (22–24), were found in the complex (Fig. 1C).
The fact that both SirT1 and HAT1 immunoprecipitations were
reciprocally detecting RIP1 strongly corroborated and strength-
ened the existence of the RIP1-HAT1-SIRT1 single complex
(Supplementary Fig. S1). The observation that both HAT1 and
SIRT1 (and 2) were detectable within the RIP1-IP prompted us
to investigate whether these acetyltransferases/deacetylases
might regulate RIP1 by (de)acetylation. By probing RIP1 immu-
noprecipitated cells with anti–acetyl-lysine antibody, we
observed the presence of an acetylated form of RIP1 (Fig.
1D). Given that RIP1 acetylation has been very debated (25)
and never proven in living cells, to investigate the location of
RIP1 acetylation sites, high-resolution tandem mass spectrom-
etry was applied. To this end, peptides resulting after digestion
with trypsin were separated and analyzed by nano-HPLC cou-
pled to an Orbitrap Q-Exactive mass spectrometer. Data-depen-
dent HCD spectra were obtained on the five most intense mass
peaks generated in each scan at resolution of 17,500. Amino
acid sequences of high confidence peptides obtained by high-
resolution tandem mass spectrometry are reported in Supple-
mentary Figs. S2, S3, and S4 and Supplementary Table S1. Five
acetylated lysine residues were identified (Fig. 1E); of these,
K115 was localized within the RIP1 kinase domain, whereas
K625, K627, K642, and K648 were mapped within the RIP1
DD, suggesting a potential role for acetylation in RIP1 kinase
and cell death–regulating functions. Given that RIP1 is local-
ized in the cytoplasm (26), HAT1 and SIRT1 location in the
different cellular compartments was studied. Interestingly,
although RIP1 confirmed exclusive cytosolic localization, HAT1
and SIRT1 were found in both nuclear and cytosolic compart-
ments, with a higher expression in the cytosol (Fig. 1F).
RIP1 acetylationmodule is enhanced by SIRT inhibition at sites
K596–K599
To assess RIP1, HAT1, and SIRT1/2 relationship, we mea-
sured RIP1 acetylation using a newly synthesized pan-SIRT
inhibitor, MC2494 (Fig. 2A; Supplementary Table S2 and
Supplementary Note), an AGK-2–related molecule (27). This
compound displays inhibitory actions against SIRT1, SIRT, and
SIRT3/4/5/6, revealing unique features when compared with
SIRT1- and 2-selective inhibitors (refs. 27–29; Fig. 2B). The IC50
values for SIRT1 and 2 inhibition were 38.5 and 58.6 mmol/L,
Figure 4.
The TRAIL–DR5 axismediatesMC2494 cell death.A, TRAIL andDR5 expression uponMC2494 (50mmol/L) for 24 to 30 hours (left), H3K9ac ChIP assay ofDR5, TRAIL
promoters followed by qPCR (right). B, SIRT1 ChIP assay at DR5 and TRAIL promoters followed by qPCR. C, Schematic representation of TRAIL promoter and
deletion mapping (top). Transient transfection assay reveals that TRAIL promoter distal boxes (containing GC-box, AP-1, and ISRE) are essential for activation by
MC2494 (bottom). D, siRNA silencing of caspase-8 or RIP1 and RIP1 pharmacologic inhibition with Necrostatine-1 (Nec-1, 100 mmol/L) abolishes MC2494
apoptosis in U937 cells. E,Apoptosis (left) and necrosis (Annexin/PI; right) assays following treatmentwithMC2494 (50mmol/L) or vehicle for 24 hours in U937 cells.
F, Western blot analysis in U937 cells shows a reduction of IAP expression, a no-modulation of CYLD, and an increment of IKKg protein levels following MC2494
treatment (50 mmol/L and 24 hours). ERKs are loading controls. G, Evaluation of RIP1-death impairment in HEK293FT cells transfected with RIP1wt or
with the RIP(K596/599R) mutant.H, Evaluation of cell death induced byMC2494 in HEK293FT cells transfected with RIP1wt or with the RIP1(K596/599R) mutant. I, Protein
expression evaluation by Western blot of acetyl lysine (top) and RIP1 (bottom) in HEK293FT cells transfected with RIP1wt and RIP(K596/599R) mutant. Graph
showed the mean of three independent experiments with error bars indicating standard deviation.
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respectively (Supplementary Fig. S5A). Although MC2494-
SIRT1 modulation was corroborated on a panel of orthogonal
in vitro assays (Supplementary Fig. S5B), MC2494 was inactive
against both HATs (PCAF) and HDACs (Supplementary Fig.
S5C and S5D), suggesting high pan-SIRT specificity. Direct
binding between Sirtuins and MC2494 was corroborated by
CETSA assay (ref. 30; Supplementary Fig. S5E). Interestingly,
although the presence of MC2494 protected SIRTs from ther-
mal degradation, SIRT1/2/3 mRNA and protein levels were
reduced in three different cancer systems by MC2494, differ-
ently from normal cells (Fig. 2C and D), assuming features of
cancer-selectivity. In agreement with the pan inhibitory action,
MC2494-induced levels of p53K382 and tubulin acetylation
were highly increased, as were H3 (K9-14ac and K56ac) and H4
acetylations (Supplementary Fig. S5F). Excitingly, a strong
increase of RIP1 acetylation was observed (Fig. 2E) upon
MC2494 stimulation strengthening a possible role of SIRTs in
modulating RIP1 (de)acetylation. Mass spectrometry analyses
were applied to corroborate these data. Under MC2494 treat-
ment conditions, no qualitative differences were detected in
RIP1 acetylation with the exception of the diacetylated peptide
592-603 ([Mþ2H]þ at m/z 777.88), containing two additional
acetylation sites (K596–K599), only detected following
MC2494 treatment (Fig. 2F). Interestingly, this region was also
identified as the top-score deacetylation site (P value: 0.015) by
the Predict(S) algorithm of the ASEB web server for lysine
acetylation/deacetylation site prediction by selecting the data-
base of 129 known deacetylation sites of SIRT1. Finally,
MC2494 regulated the newly identified RIP1 interactome,
decreasing SIRT1 expression in the complex, thus unbalancing
SIRT1 in favor of HAT1. Also HAT4 and RIP3 were still detectable
with a slight increase of RIP3 (Fig. 2G). Interestingly when the
HAT inhibitor C646was used, this drugwas able to abrogate RIP1
acetylation, corroborating the involvement of the acetyl trans-
ferases in RIP1 acetylation (Supplementary Fig. S6A). This evi-
dence is also supported by the presence of PCAF in the complex
(Supplementary Fig. S6B). Moreover, an siRNA approach was
performed to corroborate and strengthen these data. Upon SIRT1
silencing, RIP1 acetylation increased, clarifying the SIRT1-
mediated action mechanism of MC2494. (Fig. 2H). These results
indicate that RIP1 acetylation at K596–K599 is governed by SIRT
inhibition using this novel pan-SIRT inhibitor. To gain more
insights into the role of MC2494 in RIP1 acetylation, immuno-
precipitation assay was carried out in cells stimulated with one
inactive derivative of MC2494, MC2582 (Supplementary Table
S2). As expected, MC2582 has no effect on RIP1 acetylation.
(Supplementary Fig. S7).
Pan-SIRT inhibition induces caspase-8–dependent cancer-
selective cell death
To define the potential biomedical effects of pan-SIRT inhi-
bition and RIP1 complex acetylation, the action of MC2494
was investigated on both leukemia and breast cancer cells. In
contrast to EX527 (SIRT1i) and AGK-2 (SIRT2i), MC2494
induced strong proliferation arrest (Fig. 3A; Supplementary
Figs. S8 and S9C) and, importantly, did not affect cell cycle or
differentiation (Supplementary Fig. S9A and SB). When quan-
tified in real time, MC2494 reduced cell proliferation and
migration rate measured by cell index and slope at early time
points (Fig. 3B). These data strongly imply wide-ranging anti-
proliferative effects. Given the hypothesized tumor-selective
action, we evaluated the cytotoxic effect of MC2494 by com-
paring its effect on a broad panel of cancer cells and normal (or
immortalized, noncancer) cells. Notably, MC2494 induced cell
death in cancer without displaying significant cytotoxicity in
normal cells (Fig. 3C). These findings strongly suggest that cell
death induction by MC2494 is tumor-specific. Caspase-3/7, -8,
-9 activation (Fig. 3D) and dissipation of mitochondrial mem-
brane potential (MMD; Fig. 3E) were induced by MC2494 in
cancer cells as was DNA damage measured as increased expres-
sion of ATM, ATR, and gH2AX (Fig. 3F). Both players of the
extrinsic and intrinsic apoptotic pathways were modulated
(Supplementary Fig. S9D and S9E). To gain mechanistic
insights, the caspase-8 Z-IETD, caspase-9 Z-LEHD, and pan-
caspase Z-VAD inhibitors were tested for their ability to block
MC2494 action. Only Z-IETD and Z-VAD completely blocked
MC2494-induced PCD, whereas cell death was unaltered in the
presence of Z-LEHD, suggesting that caspase-9 activation is
dispensable (Fig. 3G). Interestingly, an increment of ROS
production occurred upon MC2494 treatment, indicating a
possible link between caspase activation, ROS production, and
RIP1 expression (Fig. 3H; ref. 31). Therefore, we tested the
effect of NAC (32), a known ROS scavenger. Remarkably, in
U937 cells, NAC abolished MC2494-induced PCD, demon-
strating a causal relevance for ROS production (Fig. 3H).
RIP1 and its acetylation causally activate cancer-selective cell
death pathways
To gain insights into PCD mechanism(s), we analyzed the
transcriptome of U937 cells treated with MC2494 in comparison
with cells treated with the lead SIRT1 inhibitor EX527 (Supple-
mentary Fig. S10A). The 1,245 MC2494 specifically modulated
probes were characterized for their relative abundance of Gene
OntologyBiological Processes usingDAVID (Supplementary Figs.
S10B and S11).MC2494 deregulated 116 annotated genes related
Figure 5.
MC2494 displays broad anticancer action in vitro, ex vivo, and in vivo.A, Induction of apoptosis byMC2494 (50 mmol/L) for 24 and 48 hours in 10 ex vivo primary AML
and ALL blasts. B, Representative images of two orthotopic allografted mice with 4T1-luc cells into mammary fat pad. Bioluminescence imaging levels of
vehicle- (DMSO) and MC2494-treated mice were acquired at 0 (T0) and after 7 (T7) days of daily treatment and quantified as photon/sec. See Supplementary
Table S4 for BLI data in photon/sec. Results are
P  SEM from 7 mice each in the vehicle- and MC2494-treated groups. C, MC2494 reduces subcutaneous
tumor growth of MDA-MB231 xenograft using s.c. injection of 5  106 cells into the left leg of nude mice by and its combination with electrochemotherapy. In vivo
growth in volume of tumors induced. Two controls (vehicle alone and electroporation of vehicle) are reported to exclude possible effects of the vehicle and
electroporation in vivo. In the control groups (animals treated with vehicle or electroporation), tumor volumes strongly increased over a 28-day period, whereas
MC2494 caused a significant reduction (P value 0.005 and 0.001, respectively). An even greater growth inhibition was obtained by the combination of
MC2494/electrochemotherapy (P value < 0.001) compared with both controls. The weight of all mice assigned to the various groups fell within the same range,
providing no immediate evidence for overt toxic effects. Ki67 and TUNEL scores were performed at the end of treatment. The proliferation index was significantly
lower in tumors of treated mice compared with controls (P ¼ 0.002). Apoptotic index was significantly higher in tumors of MC2494-treated mice (P ¼ 0.002).
D, Immunohistochemical analysis for the apo-index, Ki67, H3K56ac, ac-tubulin, SIRT1, SIRT2, RIP1, and KAT1/HAT1 levels in tumors. Curves and graph presented
showed the mean of at least two different experiments with error bars indicating standard deviation.
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to PCD (FDR ¼ 0.0029), suggesting that this modulation might
account for its apoptotic action (or part of it). Strikingly, among
the PCD-related targets, DR5 was selectively upregulated by
MC2494 (Supplementary Fig. S10C, P < 0,001), suggesting
that its modulation may account for a potential cancer-selective
PCD. Corroborating the transcriptome, PCR confirmed DR5
induction and supported TRAILmRNA upregulation by MC2494
already after 24 hours of induction. Interestingly, H3ac ChIP
followed by qPCR revealed strong acetylation at TRAIL and DR5
promoters after the treatment (Fig. 4A). To elucidate the acety-
lation modulation at TRAIL and DR5 promoters, SIRT1 ChIP
followed by qPCR was performed. Interestingly, SIRT1 occu-
pancy was found at those promoters and was decreased after
MC2494 treatment, suggesting an active role for SIRT1 at TRAIL
and DR5 promoters (Fig. 4B). We investigated TRAILp by a
deletion mapping approach (Fig. 4C). Whereas HDACi selec-
tively targets the proximal GC-box and complexes binding to it
(17), MC2494-dependent TRAIL activation was strongly
reduced by mutations of promoter-distal areas containing the
distal GC-box, AP-1, and ISRE. Conversely, mutation of pro-
moter-proximal GC-box led to over 2.5-fold increase,
highlighting a potential repressive role of MC2494 on chro-
matin at this region. Thus, MC2494-driven TRAIL activation
causally activates the tumor-selective TRAIL/DR5 pathway. To
extend the hypothesis that both caspase-8 and RIP1 causally act
during MC2494 PCD, we performed loss-of-function experi-
ments in U937 cells. Upon silencing of either CASP8 or RIP1,
MC2494-mediated PCD was abolished, suggesting a potential-
ly crucial link between caspase-8 activation and RIP1 function
(33) in promoting PCD by MC2494 (Fig. 4C). In support, a
similar PCD suppression was observed when pharmacological-
ly blocked RIP1 function after the coadministered with its
inhibitor Necrostatine-1 (Nec-1; ref. 34; Fig. 4D). Because RIP1
regulates different types of cell death and survival, we aimed to
further distinguish between PCD and necrosis. Data with dou-
ble Annexin V–propidium iodide (PI) staining strongly indi-
cated that MC2494, like staurosporine, only induced PCD
(Fig. 4E). Intriguingly, expression of the E3 ubiquitin ligases
IAPs is fully abrogated (ref. 35; Fig. 4E), whereas the expression
of IKKg (NEMO; ref. 36) is induced in the absence of a principal
deubiquitinating enzyme, CYLD (refs. 37, 38; Fig. 4F). Collec-
tively, the data suggest a scenario in which, following SIRT
inhibition by MC2494 treatment, a PCD pathway is activated,
with RIP1 and caspase-8 mediating death and having a causal
role. Because RIP1 is acetylated and in the presence of MC2494,
the new acetylation occurs at site 596–599 in the RIP1 DD, we
applied a mutational approach. Upon transfection in cancer
cells, RIP1-mediated cell death was reduced by about 40% with
the mutant K596–599R, suggesting that these newly acetylated
sites may regulate RIP1 apoptotic function (Fig. 4G). To
strength these data, we investigated the effect of MC2494 on
RIP1K596–599R (Fig. 4H). Although the point mutation has no
impact on the binding between HAT1 and RIP1, cell death
induction and RIP1 acetylation undergo a reduction, suggesting
the important role of these K residues in driving anticancer
activity of MC2494 (Fig. 4I).
MC2494 exerts cancer cell–selective action ex vivo and in vivo
For primary cancers, acute leukemia blasts were treated ex
vivo with MC2494 showing a strong increment in pre-G1 phase
(Fig. 5A). MC2494-mediated PCD was clearly detectable at 24
and 48 hours in all 9 primary acute myeloid leukemia (AML)
blasts and one acute lymphoid leukemia (ALL) blast, under-
scoring that in primary cancer, MC2494 induces apoptosis (Fig.
5A; Supplementary Table S3). Pharmacokinetic and in vitro
half-life studies strengthened a possible use of MC2494 in vitro
and in vivo (Supplementary Fig. S12A–S12D). In vivo, MC2494
strongly reduced tumor growth in allograft models as quanti-
fied by direct photon emission of luciferase-expressing immu-
nocompetent mice (Fig. 5B; Supplementary Table S4). More-
over, the MDA-MB-231 breast cancer–based xenograft model
treated with MC2494 displayed a strong anticancer effect vis-
ible as decreased tumor mass. When MC2494 was inoculated
by in vivo chemoelectroporation, the anticancer effect increased,
suggesting its potential in vivo also in superficial tumors (as
melanoma or other skin tumors in rapid proliferation; Fig. 5C).
Following MC2494, apoptosis (tunnel assay), histone and
nonhistone SIRT targeting, SIRT1, SIRT2, RIP1, and KAT1/
HAT1 were observed in tumors (Fig. 5D), extending results
obtained in cell lines.
MC2494 exerts cancer-preventive action in vivo
It is a widely shared opinion that cancer prevention is a better
approach than treatment. A strategy might include prevention of
cancer recurrences and/or action in genetically predisposed
patients. Thus, we evaluated the ability of MC2494 to prevent
early proliferation occurring inmammary glands after carcinogen
exposition. Twogroups ofMITO-Luc reportermice (ref. 19; online
Methods) were subcutaneously treated with a daily dose of 50
mg/kgMC2494 or placebo (corn oil) for 9 days (9D); at D6, right
and left mammary glands were exposed to DMBA or vehicle,
respectively. As expected, 3D after DMBA injection in the left
mammary gland, bioluminescent emission was detectable in
the mice pretreated with placebo (Fig. 6A, placebo). Excitingly,
no bioluminescence was detected in the MC2494-pretreated
animals, suggesting that the compoundwas able to fully abrogate
DMBA-induced malignant proliferation in vivo (Fig. 6A–C).
In keeping with these data, Ki-67 proliferation marker was
Figure 6.
MC2494 exerts cancer-preventive effects in vivo.A,Optical imaging analysis of bioluminescence fromMITO-Luc reporter mice injected in themammary fat padwith
DMBA (left) or vehicle (right gland); bioluminescent emission is represented using a pseudo-color scale. Magnified inserts highlight details of photon emission
from mammary glands. B, Quantitation of A. Bars represent average photon emission  SEM from 4 animals/group measured within the mouse areas shown
in the magnified inserts inA; bioluminescent emission is completely prevented in MC2494 group as compared with placebo.  , P < 0.001 DMBA (n¼ 4) vs. vehicle-
treated (n ¼ 4) mammary glands calculated using unpaired t test. C, Ex vivo imaging of mammary glands from two representative mice from each group. D,
Immunohistochemistry of breast slices obtained fromeach group stained for Ki67 antibody reveals amarked reduction of cell proliferation in theDMBAþMC2494 as
compared with DMBA. E, Quantitation of immunohistochemistry in D. Bars represent the average  SEM of the Ki67 index expressed as the ratio between Ki67-
positive cells vs. total.  , P < 0.001 DMBA- vs. vehicle-treated mammary glands calculated using two-way ANOVA followed by the Bonferroni post hoc test. F,
Immunohistochemistry and relative quantization of H3K9 acetylation on breast slices obtained from each group; and increased H3K9ac is visible in MC2494-treated
animals, corroborating SIRT1/2 inhibition in vivo. Graph showed the mean of three independent experiments with error bars indicating standard deviation.
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highly expressed in themammary glands treated withDMBA (Fig.
6D, lower plot, left), but to a much lower extent in glands
explanted from MC2494-pretreated mice (Fig. 6D lower plot,
right, and Fig. 6E). Increased acetylation of H3K9 in tissues
obtained fromMC2494-treatedmice confirmed that theMC2494
was inhibiting this and likely other epi-targets (Fig. 6F; Supple-
mentary Fig. S11). These experiments suggest that MC2494
counteracts hyperproliferation occurring during the early steps
of carcinogenesis, strongly supporting that MC2494 is not only
active against an "on-going" cancer, but also acts in a cancer-
preventive manner in vivo.
Discussion
Our study identifies a new role for Sirtuins and HATs (mainly
HAT1; ref. 39) in modulating programmed death pathways.
This occurs via a newly identified RIP1–SIRT1/2/HAT1-contain-
ing complex and via regulation of RIP1 acetylation. RIP1 (and
its acetylation) might represent a key regulatory restriction
point between survival, stress, and death. In full agreement,
MC2494, a novel pan-SIRT inhibitor (SIRTi; ref. 40), alters the
HAT1/SIRT equilibrium in the RIP1 complex. The fact that our
MS approach combined with affinity-based chromatography
enrichment reveals not only the existence of the RIP1/KAT1/
SIRT axes, but also the presence of seven RIP1 acetylation sites
(the majority of which are in the DD) adds to a possible
regulatory role for acetylation of RIP1-mediated death. In
support, mutation of K596–599 to arginine alters RIP1 apo-
ptotic function, suggesting its complex regulation by posttrans-
lational modifications.
The finding that RIP1 is a main player in PCD represents a
paradigm shift, identifying (acetylated) RIP1 as an apoptotic
player altered in cancer and a potential target of intervention.
Based on our findings, we hypothesized that Sirtuins play a key
role in restricting RIP1-caspase-8 apoptosis in cancer. The
importance of caspase-8 is demonstrated by its causal role,
because pharmacologic inhibition and silencing fully block
SIRTi-driven death. Pan-SIRT inhibition–mediated anticancer
activity is also causally linked to ROS and RIP1, given that
treatment with both NAC and Nec-1, and RIP1 silencing,
abolishes PCD. Whether this action also accounts for the
tumor-specificity of the pan-SIRTi remains to be established.
Evidence that both TRAIL and DR5 are upregulated upon
treatment is reminiscent of findings that we (and others; ref. 41)
reported for HDACi (17). The contribution of TRAIL tumor-
selective PCD by SIRTi is unlikely attributable to HDAC inhi-
bition as MC2494 does not affect the activity of HDACs.
Second, cis-acting elements responsible for MC2494 TRAIL
transcriptional activation are distinct from those reported for
HDACi (17). Although our findings strongly suggest that anti-
cancer action of pan-SIRTi can be linked to RIP1 acetylation
and TRAIL–DR5 axis activation in cancer (42), the possible
tumor-selective activity of pan-SIRTi via TRAIL is a key element
because normal cells of diverse origin are all insensitive to pan-
SIRT inhibition. Although the role of oxidative stress in TRAIL-
mediated apoptosis has been reported (43), our data show that
impairment of either caspase-8 or RIP1 fully blocks SIRTi action
and that RIP1 acetylation mutant is blandly able to regulate cell
death. Possibly, the presence of 7 different RIP1 acetylation
sites (only 2 of which are modulated in these settings by SIRTi)
suggests that acetylation might control RIP1 cell death
functions in a very defined manner. These evidences propose
the existence of a caspase-8/RIP1ac-dependent death paradigm
of cell death, bound to epigenetic players such as (but not
restricted to) Sirtuins and type-B HATs (HAT1; ref. 44). Inter-
estingly, SIRT1 interferes with apoptosis induced by oxidative
stress, deacetylating and activating FOXO1 (45), FOXO3a (46),
and FOXO4 (47), inducing GADD45 and the mitochondrial
antioxidant manganese superoxide dismutase. Each of these
factors might contribute to ROS tolerance by SIRT1 alteration
in cancer. Deregulation of ROS production, oxidative stress,
and FOXO activity are essential steps in cancer development
and progression. Moreover, SIRTi induction of apoptosis is
accompanied by a marked reduction of IAP and FLICE-inhib-
itory protein (c-FLIP). Interestingly, IAP reduction (and DR5
activation co-occurrence) was recently reported combining IAP
inhibitors with lexatumumab (48). This combination results in
apoptosis and vanquish cancer resistance by caspase-8/RIP1ac
activation. Thus, new therapeutic regimens may involve SIRTi
and remodulation of the RIP1-containing complexes in cancer
bypassing resistance to conventional drugs. Consistently, both
xenograft and allograft in vivo cancer models responded to SIRT
inhibition with arrest of progression and disease regression
along with increase in apoptotic markers, block of prolifera-
tion, SIRT and HAT1 expression resetting, and acetylation
within tumors. Ex vivo leukemia blasts also undergo PCD upon
pan-SIRT inhibition, suggesting a broad range of anticancer
actions by MC2494. Though a number of anticancer studies
involving SIRTi in vivo have been reported (49, 50), to our
knowledge, cancer prevention in vivo has never been described.
The ability of pan-SIRT inhibition to fully prevent chemically
induced breast carcinogenesis, concomitantly increasing acet-
ylation in vivo, ex vivo, and during quantitative measurements,
shows its potential use in cancer-preventive settings, which has
not been demonstrated before in vivo. These preventive features
might prove useful in patients who may benefit from a recur-
rence-preventive approach with low toxicity during follow-up
phases and in cases of established cancer predisposition.
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